Back to Screener

Brainsway Ltd. American Depositary Shares (BWAY)

Price$15.68

Favorite Metrics

Price vs S&P 500 (26W)74.53%
Price vs S&P 500 (4W)-1.65%
Market Capitalization$1.86B
P/E Ratio (Annual)212.04x

All Metrics

P/CF (Annual)60.15x
Book Value / Share (Quarterly)$1.84
P/TBV (Annual)7.29x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)11.41%
Cash Flow / Share (Quarterly)$0.48
Price vs S&P 500 (YTD)45.41%
Gross Margin (TTM)74.92%
Net Profit Margin (TTM)12.73%
EPS (TTM)$0.15
10-Day Avg Trading Volume0.09M
EPS Excl Extra (TTM)$0.15
Revenue Growth (5Y)12.17%
EPS (Annual)$0.08
ROI (Annual)4.30%
Gross Margin (Annual)74.56%
Net Profit Margin (5Y Avg)-20.28%
Cash / Share (Quarterly)$1.88
P/E Basic Excl Extra (TTM)99.13x
Revenue Growth QoQ (YoY)28.66%
P/E Normalized (Annual)212.04x
ROA (Last FY)3.10%
Revenue Growth TTM (YoY)27.08%
EBITD / Share (TTM)$0.11
ROE (5Y Avg)-14.71%
Operating Margin (TTM)5.78%
Cash Flow / Share (Annual)$0.17
P/B Ratio8.84x
P/B Ratio (Quarterly)4.57x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)11.32x
Net Interest Coverage (TTM)-42.43x
ROA (TTM)5.96%
EPS Growth QoQ (YoY)102.02%
EV / EBITDA (TTM)117.43x
EPS Incl Extra (Annual)$0.08
Current Ratio (Annual)5.19x
Quick Ratio (Quarterly)3.02x
3-Month Avg Trading Volume0.12M
52-Week Price Return153.31%
EV / Free Cash Flow (Annual)85.44x
P/E Incl Extra (TTM)99.13x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.61
P/S Ratio (Annual)15.10x
Asset Turnover (Annual)0.43x
52-Week High$4930.00
Operating Margin (5Y Avg)-19.52%
EPS Excl Extra (Annual)$0.08
CapEx CAGR (5Y)2.77%
Tangible BV CAGR (5Y)21.08%
26-Week Price Return83.27%
Quick Ratio (Annual)4.87x
13-Week Price Return20.68%
Total Debt / Equity (Annual)0.09x
Current Ratio (Quarterly)3.19x
Enterprise Value$555.673
Revenue / Share Growth (5Y)0.93%
Asset Turnover (TTM)0.47x
Book Value / Share Growth (5Y)8.75%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)8.43%
Cash / Share (Annual)$1.84
3-Month Return Std Dev49.40%
Gross Margin (5Y Avg)75.40%
Net Income / Employee (TTM)$0
EBITDA Interim CAGR (5Y)15.11%
ROE (Last FY)4.69%
Net Interest Coverage (Annual)-3.23x
EPS Basic Excl Extra (Annual)$0.08
P/FCF (TTM)33.77x
Receivables Turnover (TTM)11.35x
EV / Free Cash Flow (TTM)30.30x
Total Debt / Equity (Quarterly)0.10x
EPS Incl Extra (TTM)$0.15
Receivables Turnover (Annual)9.79x
ROI (TTM)8.67%
P/S Ratio (TTM)12.62x
Pretax Margin (5Y Avg)-19.38%
Revenue / Share (Annual)$1.18
Tangible BV / Share (Annual)$0.76
Price vs S&P 500 (52W)168.06%
P/E Ratio (TTM)99.13x
EPS Growth TTM (YoY)231.19%
Year-to-Date Return48.67%
5-Day Price Return6.80%
EPS Normalized (Annual)$0.08
ROA (5Y Avg)-9.73%
Net Profit Margin (Annual)7.12%
Month-to-Date Return8.45%
Cash Flow / Share (TTM)$-1.31
EBITD / Share (Annual)$0.05
Operating Margin (Annual)3.39%
LT Debt / Equity (Annual)0.00x
P/CF (TTM)27.81x
ROI (5Y Avg)-14.49%
P/E Excl Extra (TTM)99.13x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$0.15
P/TBV (Quarterly)10.17x
P/B Ratio (Annual)3.51x
Inventory Turnover (TTM)3.04x
Pretax Margin (TTM)14.06%
Book Value / Share (Annual)$1.66
Price vs S&P 500 (13W)17.81%
Beta0.27x
P/FCF (Annual)95.23x
Revenue / Share (TTM)$1.25
ROE (TTM)9.46%
52-Week Low$1444.00

Industry Peers — Surgical & Medical Instruments(108)

SymbolP/S Ratio (TTM)Revenue Growth (5Y)Gross Margin (TTM)Operating Margin (TTM)Price
BWAYBrainsway Ltd. American Depositary Shares
12.62x12.17%74.92%5.78%$15.68
SYKStryker Corporation
5.17x11.84%64.57%19.43%$338.34
BSXBoston Scientific Corp.
4.58x15.16%69.01%18.00%$60.99
MMM3M Company
3.21x-4.97%39.92%18.55%$151.40
MDLNMedline Inc. Class A common stock
2.20x26.44%7.78%$48.26
BDXBecton, Dickinson and Co.
2.06x6.32%46.42%12.15%$158.64
RMDResMed Inc.
6.07x11.72%60.85%33.70%$226.14
DXCMDexCom, Inc.
5.33x19.33%62.09%19.56%$64.62
WSTWest Pharmaceutical Services, Inc.
6.29x7.44%35.91%19.03%$278.00
PODDInsulet Corporation
5.19x24.53%71.63%12.92%$200.87
PENPenumbra, Inc.
9.24x20.16%67.14%13.48%$329.71

About

BrainsWay Ltd develops Deep Transcranial Magnetic Stimulation (Deep TMS), a noninvasive neurostimulation platform for treating mental health and neurological disorders. The company currently generates revenue through lease and sale of Deep TMS systems for FDA-approved indications including major depressive disorder, obsessive-compulsive disorder, and smoking addiction. Additional clinical trials are underway to expand the platform's therapeutic applications across psychiatric, neurological, and addiction disorders.